#Alcobra Ltd

[columbianewsupdates]

Fragile X Syndrome Pipeline Insight and Clinical Trials Assessment (2023) | Companies- Zynerba Pharma, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd, and others

http://dlvr.it/Sqcm7R

[technewspoint]

Fragile X Syndrome Pipeline Insight and Clinical Trials Assessment (2023) | Companies- Zynerba Pharma, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd, and others

http://dlvr.it/Sqccp8

[newsupdated]

Stocks making the biggest moves premarket: Boeing, SAP, Lemonade, Alibaba & more

Stocks making the biggest moves premarket: Boeing, SAP, Lemonade, Alibaba & more

[latestbreakingnewsupdates]

Singapore greenlights clinical trials for vaccine candidate developed by Arcturus and Duke-NUS Medical School

Singapore greenlights clinical trials for vaccine candidate developed by Arcturus and Duke-NUS Medical School

Singapore’s Health Sciences Authority has permitted clinical trials for a coronavirus vaccine candidate being developed by Arcturus Therapeutics and Duke-NUS Medical school.

Arcturus, a San Diego, California-based biopharmaceutical firm, in partnership with Singapore’s Duke-NUS stated they’ll start human dosing assessments as quickly as doable.

In a joint assertion, the corporate and medical…

[miamiroofing162]

Alcobra LTD (ADHD) Valuation Declined While Knoll Capital Management LP Trimmed Holding ...

Spitfire Capital Llc who had been investing in Beacon Roofing Supply Inc for a number of months, seems to be bullish on the $3.70B market cap company. The stock increased 1.42% or $0.76 during the last trading session, reaching $54.46. About 362,938 shares traded. Beacon Roofing Supply, Inc.

[houstonroofing161]

Alcobra LTD (ADHD) Valuation Declined While Knoll Capital Management LP Trimmed Holding ...

Spitfire Capital Llc who had been investing in Beacon Roofing Supply Inc for a number of months, seems to be bullish on the $3.70B market cap company. The stock increased 1.42% or $0.76 during the last trading session, reaching $54.46. About 362,938 shares traded. Beacon Roofing Supply, Inc.

[nzisraelnews]

Financial Contrast: Aclaris Therapeutics (ACRS) vs. Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked ... http://bit.ly/2EApRZ7

[newsupdated]

Stocks making the biggest moves midday: Snap, Boeing, Alibaba, Lemonade & more

Stocks making the biggest moves midday: Snap, Boeing, Alibaba, Lemonade & more

[investorshangout]

$ADHD Stock Live Analysis 10-18-2017 Alcobra Ltd. #ADHD

$ADHD Stock Live Analysis 10-18-2017 Alcobra Ltd. #ADHD http://dlvr.it/PwMhnM

[speculatingstocks]

$ADHD $OSTK are trending stocks now at SpeculatingStocks.com, the discovery engine and social network for investors #stocks

http://www.speculatingstocks.com/?TrSt=Alcobra Ltd.

[strategyr-blog]

The Global Market for ADHD Therapeutics is Projected to Cross US$25 Billion by 2022

Growing Awareness Over the Importance of Mental Healthcare and Establishment of Clinical Practice Guidelines for Diagnosis and Treatment to Drive the ADHD Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market. The global market for ADHD Therapeutics is projected to cross US$25 billion by 2022, driven by growing public awareness and gradual dissipation of social stigma associated with psychiatric disorders and the implementation of formal clinical practice guidelines for diagnosis and treatment.

Attention Deficit Hyperactivity Disorder (ADHD), also known as Attention Deficit Disorder (ADD)/ Hyper Kinetic Disorder (HKD) or Neuropsychiatric Disorder, is one of the most common diseases afflicting nearly 5.3% to 7.1% of children and adolescents as well as 3.4% of adults globally. With increased awareness, easy access to behavioral healthcare services, changes in diagnostic criteria and improved ADHD medications, the market continues to witness growth. Although historically made up of children and adolescents, adults currently represent the fastest growing patient cluster for ADHD therapeutics largely because of improvements in behavioral diagnostics and evaluation techniques which reveal a surprisingly high percentage of patients with childhood ADHD carry clinically significant symptoms well into adulthood. Addressable market opportunity therefore is poised to receive a boost from the development of algorithm and guidelines for the evaluation, diagnosis, treatment, and monitoring of ADHD in adults. Formal guidelines added in the latest edition of Diagnostic Statistical Manual of Mental Disorders (DSM) will therefore boost diagnosis rates for adult patients.

Although currently mired in uncertainty over Trump's proposed healthcare reforms, the Affordable Care Act (Obamacare Act) until now played a major role in encouraging growth in the ADHD drugs market in the United States. The act makes it obligatory for insurance providers to provide coverage for mental health services which also includes assessment of behavioral disorder and treatments. This has led to increased number of parents seeking medical aid for their children afflicted with ADHD, which they previously were unable to due to cost concerns. In view of the huge unmet needs in terms of treatment options, and better diagnostic tests, pharma companies are stepping up their investments in the development of novel new generation drugs for ADHD.

As stated by the new market research report on Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, the United States accounts for the bulk of global revenues. Asia-Pacific ranks as one of the fastest growing markets with a CAGR of 7.3% over the analysis period, led by factors such as growing population and a parallel increase in healthcare burden, development of healthcare infrastructure; establishment of several self-help groups and support systems as a result of growing awareness of hyperactivity as a behavioral disorder; and gradual easing of barriers to mental healthcare access such as cost and affordability and availability of qualitied mental health professionals.  

Major players covered in the report include Alcobra Ltd., Amarantus Bioscience Holdings, Inc., Amedra Pharmaceuticals LLC, Curemark, LLC., Eli Lilly and Company, Intellipharmaceutics International, Inc., Janssen Global Services, LLC, Mallinckrodt PLC, Mylan N.V., Neos Therapeutics, Inc., Neurovance, Inc., Noven Pharmaceuticals, Inc., Pfizer Inc., Shire plc, Supernus Pharmaceuticals, Inc., and Tris Pharma, Inc., among others.

The research report titled "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.  

 Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.

[vernelllintner]

Alcobra’s ADHD drug fails late-stage study

(Reuters) – Israeli drug developer Alcobra Ltd on Tuesday said its experimental drug to treat attention deficit hyperactivity disorder (ADHD) failed a late-stage study in adult patients.

http://reut.rs/2iCtHEJ

from WordPress http://bit.ly/2jFqlSZ